Cargando…

Mitochondrial dysfunction in fibrotic diseases

Although fibrosis is a common pathological feature of most end-stage organ diseases, its pathogenesis remains unclear. There is growing evidence that mitochondrial dysfunction contributes to the development and progression of fibrosis. The heart, liver, kidney and lung are highly oxygen-consuming or...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xinyu, Zhang, Wei, Cao, Qingtai, Wang, Zeyu, Zhao, Mingyi, Xu, Linyong, Zhuang, Quan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474731/
https://www.ncbi.nlm.nih.gov/pubmed/32963808
http://dx.doi.org/10.1038/s41420-020-00316-9
_version_ 1783579374978596864
author Li, Xinyu
Zhang, Wei
Cao, Qingtai
Wang, Zeyu
Zhao, Mingyi
Xu, Linyong
Zhuang, Quan
author_facet Li, Xinyu
Zhang, Wei
Cao, Qingtai
Wang, Zeyu
Zhao, Mingyi
Xu, Linyong
Zhuang, Quan
author_sort Li, Xinyu
collection PubMed
description Although fibrosis is a common pathological feature of most end-stage organ diseases, its pathogenesis remains unclear. There is growing evidence that mitochondrial dysfunction contributes to the development and progression of fibrosis. The heart, liver, kidney and lung are highly oxygen-consuming organs that are sensitive to mitochondrial dysfunction. Moreover, the fibrotic process of skin and islet is closely related to mitochondrial dysfunction as well. This review summarized emerging mechanisms related to mitochondrial dysfunction in different fibrotic organs and tissues above. First, it highlighted the important elucidation of mitochondria morphological changes, mitochondrial membrane potential and structural damage, mitochondrial DNA (mtDNA) damage and reactive oxidative species (ROS) production, etc. Second, it introduced the abnormality of mitophagy and mitochondrial transfer also contributed to the fibrotic process. Therefore, with gaining the increasing knowledge of mitochondrial structure, function, and origin, we could kindle a new era for the diagnostic and therapeutic strategies of many fibrotic diseases based on mitochondrial dysfunction.
format Online
Article
Text
id pubmed-7474731
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-74747312020-09-21 Mitochondrial dysfunction in fibrotic diseases Li, Xinyu Zhang, Wei Cao, Qingtai Wang, Zeyu Zhao, Mingyi Xu, Linyong Zhuang, Quan Cell Death Discov Review Article Although fibrosis is a common pathological feature of most end-stage organ diseases, its pathogenesis remains unclear. There is growing evidence that mitochondrial dysfunction contributes to the development and progression of fibrosis. The heart, liver, kidney and lung are highly oxygen-consuming organs that are sensitive to mitochondrial dysfunction. Moreover, the fibrotic process of skin and islet is closely related to mitochondrial dysfunction as well. This review summarized emerging mechanisms related to mitochondrial dysfunction in different fibrotic organs and tissues above. First, it highlighted the important elucidation of mitochondria morphological changes, mitochondrial membrane potential and structural damage, mitochondrial DNA (mtDNA) damage and reactive oxidative species (ROS) production, etc. Second, it introduced the abnormality of mitophagy and mitochondrial transfer also contributed to the fibrotic process. Therefore, with gaining the increasing knowledge of mitochondrial structure, function, and origin, we could kindle a new era for the diagnostic and therapeutic strategies of many fibrotic diseases based on mitochondrial dysfunction. Nature Publishing Group UK 2020-09-05 /pmc/articles/PMC7474731/ /pubmed/32963808 http://dx.doi.org/10.1038/s41420-020-00316-9 Text en © The Author(s) 2020 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Li, Xinyu
Zhang, Wei
Cao, Qingtai
Wang, Zeyu
Zhao, Mingyi
Xu, Linyong
Zhuang, Quan
Mitochondrial dysfunction in fibrotic diseases
title Mitochondrial dysfunction in fibrotic diseases
title_full Mitochondrial dysfunction in fibrotic diseases
title_fullStr Mitochondrial dysfunction in fibrotic diseases
title_full_unstemmed Mitochondrial dysfunction in fibrotic diseases
title_short Mitochondrial dysfunction in fibrotic diseases
title_sort mitochondrial dysfunction in fibrotic diseases
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474731/
https://www.ncbi.nlm.nih.gov/pubmed/32963808
http://dx.doi.org/10.1038/s41420-020-00316-9
work_keys_str_mv AT lixinyu mitochondrialdysfunctioninfibroticdiseases
AT zhangwei mitochondrialdysfunctioninfibroticdiseases
AT caoqingtai mitochondrialdysfunctioninfibroticdiseases
AT wangzeyu mitochondrialdysfunctioninfibroticdiseases
AT zhaomingyi mitochondrialdysfunctioninfibroticdiseases
AT xulinyong mitochondrialdysfunctioninfibroticdiseases
AT zhuangquan mitochondrialdysfunctioninfibroticdiseases